Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) is not known to cause spots as a recognised side effect — the medicine's licensed side-effect profile is dominated by gastrointestinal symptoms such as nausea and changes in appetite, with no direct link to acne or new spot outbreaks established in clinical trial data. That said, a small number of people do report skin changes, and understanding why requires looking at what the treatment actually does to your body. Mounjaro is a prescription-only medicine; whether it is suitable for you is assessed by a GPhC-registered prescriber, not a self-checklist.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
If you have been searching to find out whether Mounjaro does cause spots, the most useful starting point is the official UK prescribing information. The Mounjaro Summary of Product Characteristics (available on the Electronic Medicines Compendium (eMC)) lists its common and very common side effects. Nausea, vomiting, diarrhoea, constipation and indigestion feature prominently. Injection-site reactions (redness, bruising, mild swelling, a raised lump at the puncture point) are also documented. Spots, acne, or any broader skin eruption do not appear in that recognised list.
That matters, because the SURMOUNT clinical trials tested tirzepatide in thousands of adults over 72 weeks, a long enough window that recurring skin effects would likely have surfaced in the safety data. They did not emerge as a signal. The absence of a recognised link is itself clinically informative, even if it does not mean nobody's skin ever changes during treatment.
For a fuller picture of what the licensed side-effect profile covers, the NHS tirzepatide medicines page sets this out in plain language and is worth reading before you start or if new symptoms appear.
The body does not respond to a significant shift in eating patterns in isolation. When calorie intake falls and diet composition changes rapidly, hormonal fluctuations can follow, particularly around insulin sensitivity, androgens and cortisol. For people who are prone to hormonal acne, those shifts can occasionally provoke a breakout early in treatment. This is not a pharmacological effect of tirzepatide itself; it is more plausibly a downstream consequence of metabolic change.
There is also a practical factor worth naming. People on tirzepatide often describe feeling different about food within the first few weeks: less appetite, altered taste preferences, sometimes an unintentional narrowing of diet. If that means fewer vegetables, less water, or a temporary lean on processed convenience foods while adjusting, skin quality can suffer for entirely nutritional reasons. Keeping protein and hydration up matters, and it is easier to remember if your routine already has a prompt, like a glass of water when you take your weekly dose from the fridge door.
To understand whether skin effects you are noticing are connected to tirzepatide more broadly, the overview of Mounjaro and spots and the related page on Mounjaro and spots specifically on the face go into further depth on the possible mechanisms.
One source of confusion is worth addressing directly. A raised, reddened or itchy lump at the injection site can look worryingly spot-like if you have not seen one before. These local reactions are different in character and cause from a facial or body spot: they arise because a needle has broken the skin, and the immune system is responding locally. They typically fade within a few days.
Rotating your injection site (between abdomen, thigh and upper arm, as described in the patient leaflet) reduces the chance of a reaction building at any one point. If a site reaction is painful, hot to touch, spreading, or persists beyond a week, that warrants a conversation with your prescriber rather than self-management.
For a detailed look at whether Mounjaro gives you spots and how to distinguish injection-site effects from other skin changes, our dedicated page covers that distinction closely. If you want to understand how the treatment works at a biochemical level, the tirzepatide guide covers its dual GIP and GLP-1 receptor mechanism in full.
Most skin changes that coincide with starting Mounjaro are benign and settle as the body adjusts. The situations that warrant a clinical conversation include: a rash that is widespread, blistering, or accompanied by fever; a severe injection-site reaction that is not improving; or any allergic symptoms (swelling of the face or throat, difficulty breathing). These are potential signs of a serious reaction and need urgent medical attention.
Cosmetic concerns (a few new spots, slightly oilier skin in the first month) are lower urgency but still worth mentioning at your next review. A prescriber who knows your full picture can rule out other causes, check whether any other medicines you take might interact with tirzepatide, and advise on whether the timing matches a dose change. If you are already a patient with us, our aftercare team is available seven days a week via our contact page.
If you are considering starting treatment and want to understand the benefits of Mounjaro alongside its realistic side-effect profile, or if you would like to explore weight-loss treatment options more broadly before deciding, those resources are a good place to start. When you are ready to talk to a clinician, starting a free consultation takes a few minutes, a real prescriber reads your responses the same day, never an automated system. If menstrual changes are among the symptoms you have noticed, our page on whether Mounjaro causes spotting addresses that specific concern in detail.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.